Laurus Labs Ltd held an earnings call on July 25, 2025, discussing their Q1 FY26 results, including plans to increase CDMO revenue from over 30% currently to potentially 50% in the future, and a new 6,000 square meter facility in Hyderabad for gene therapy and antibody drug conjugate production.